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protein, while the latter (P145L) is likely caused by defective dimerization as observed in the Y2H analysis.
Allele-specific perturbations of CBS mutant proteins were found to be associated with a treatment response. Pyridoxine, a precursor of the CBS cofactor pyridoxal phosphate (PLP), alleviates CBS deficiency and reduces the associated disease symptoms (Mudd et al., 1985) . Not all patients respond to pyridoxine. A patient with the wild-type-like P422L allele is not pyridoxine responsive (Maclean et al., 2002) , suggesting that increased PLP cofactor does not enhance CBS enzyme activity of alleles with presumably largely unaffected structure. Patients carry the alleles with partial loss of protein interactions, P145L (Kozich et al., 1993) or L539S (Aral et al., 1997) , are pyridoxine responsive, consistent with partially perturbed protein structures that may be stabilized by cofactor binding. Some patients with the null-like I278T allele are reportedly pyridoxine responsive (Kluijtmans et al., 1999) . However, it was recently suggested that the mechanism of pyridoxine responsiveness in I278T patients may involve mechanisms besides direct enhancement of CBS activity by PLP (Chen et al., 2006) . The null-like interaction profile of I278T also supports a grossly altered structure, unlikely to be directly restored by cofactor binding.
HGD (homogenistate dioxygenase)
Mutations in HGD give rise to Alkaptonuria, a benign inborn error of metabolism characterized by excess homogentisic acid in body fluids, causing several symptoms including "black urine" (Garrod, 1902; Phornphutkul et al., 2002) . Five disease-causing mutant alleles from HGMD distributed along the coding sequence of HGD were cloned and tested for interactions against three interactors of the respective wild-type protein identified in our screen (HGD, NUDT18, NIF3L1) ( Figure S3A ). We found a similar distribution of allele classes:
alleles that are null with respect to all tested protein-protein interactions (V300G and E42A), a pseudo-wild-type allele (H371R), and alleles causing interactionspecific perturbation to HGD (R225H and L25P) ( Figure S3A ).
Three-dimensional structure is available for HGD . Similar to CBS, the null-like allele (V300G) also has non-conservative amino acid substitutions in the highly structured internal regions of the protein ( Figure S3B ), possibly grossly disrupting protein conformation. The other null allele (E42A) likely causes defects in HGD oligomerization, since the E42 residue forms a saltbridge with the three-fold related Arg336 in the HGD hexamer. Both null alleles (V300G and E42A) have dramatically loss of enzyme activity ( Figure S3D ).
Alleles causing interaction-specific defects (R225H and L25P) correspond to mutated residues on the surface of the protein ( Figure S3B ). The Arg225 and Leu25 residues participate in the dimerization of HGD trimers. Substitution of these residues by His and Pro, respectively, should not affect trimerization of the hexamer, given the nature of the substitutions and of the two-fold interface of HGD oligomer. The edgetic allele (R225H) with nearly complete loss of enzyme activity ( Figure S3D ) showed clearly reduced dimerization in the Y2H analysis ( Figure S3A ), possibly leading to defective hexamer formation. The pseudo-wildtype allele (H371R) also has mutated residues on the surface ( Figure S3B ). The side chain of His371 directly coordinates the cofactor Fe 2+ . Therefore the H371R mutant allele is likely defective for ligand binding leading to loss of enzyme activity ( Figure S3D ) .
ACTG1 (cytoplasmic γ-actin)
Five mutations in ACTG1 are associated with progressive, sensorineural hearing loss as annotated in HGMD. Profiling of deafness-associated ACTG1 alleles revealed wild-type-like and interaction-specific perturbations. Three ACTG1 alleles (T89I, K118M, and T278I) retain all wild-type interactions ( Figure S4A ). Of these, Thr89 and Thr278 are completely buried in the structure of the ortholog bovine β-actin (Chik et al., 1996) , and the K118M substitution modifies the physicochemical properties of the solvent-exposed Lys118 residue ( Figure S4B ).
The lack of interaction defects in these disease-causing alleles may simply result from the few interactions that were analyzed. Thr89 is implicated in an interaction with an actin bundling protein, fimbrin (Adams and Botstein, 1989) , but this interaction was not tested here. Two mutations (P264L and P332A) show severe interaction defects with actin depolymerizing factors (CFL1, CFL2, and DSTN) ( Figure S4A ), suggesting defective actin dynamics leading to hearing loss.
Pro264 is buried in the bovine β-actin structure ( Figure S4B ), mutation of which likely results in structural alterations. Pro332 is surface exposed ( Figure S4B ) and falls into one of the five biochemically identified peptide stretches (328) (329) (330) (331) (332) (333) (334) (335) (336) (337) (338) that mediate binding of actin to cofilin (Mannherz et al., 2007) . All five ACTG1 mutant alleles preserve interactions with wild-type β-actin (ACTB) and γ-actin (ACTG1) ( Figure S4A ), consistent with possible incorporation of mutant monomers in actin filaments in vivo, causing dominant negative effects.
CDK4 (cyclin dependent kinase 4)
CDK4 controls cell cycle progression and is negatively regulated by cyclindependent kinase inhibitors (Ortega et al., 2002) . Four CDK4 germline mutations are annotated in HGMD with increased risk of melanoma. All four CDK4 mutant alleles were cloned and tested for interactions against three previously identified interactors (Rual et al., 2005) , and another known CDK4 inhibitor available in our human ORFeome collection (Lamesch et al., 2007) , CDKN2C (cyclin-dependent kinase inhibitor 2C). Both R24H and R24C mutant alleles show reduced interaction with CDKN2C ( Figure S5A ), consistent with available crystallographic data and oncogenic activation of CDK4. The other two mutations (N41S and S52N) affect residues in the vicinity of cyclin binding site but do not make direct contact with D-type cyclin in the crystal structures (Day et al., 2009 ) ( Figure   S5B ). N41S was found in the germline of a patient with no family history of melanoma (Guldberg et al., 1997) . S52N was found in a family with a history of melanoma but this mutation is not carried by all affected individuals (Holland et al., 1999) . The conservative nature of these mutations and their unaffected interaction profile in Y2H strongly suggest that the pathological relevance for these two alleles is uncertain. To test the possibility that CDK4 mutant alleles may gain new interactions, we carried out Y2H screens for both the wild-type and four mutant CDK4 proteins against a set of ~12,200 human open reading frames (Lamesch et al., 2007) . However, at this stage we did not recover any gain-ofinteraction for any of the four mutant CDK4 proteins yet.
PRKAR1A (cAMP-dependent protein kinase type Iα regulatory subunit)
Mutations in PRKAR1A are associated with Carney complex, a multiple neoplasia syndrome. About 90% of PRKAR1A mutations recorded in HGMD result in premature stop codons or frameshifts (9 nonsense, 1 missense, 4 inframe and 26 out-of-frame insertions or deletions, and 12 splice site mutations).
PRKAR1A regulates one of the two types of PKA, type I PKA. Reduced PRKAR1A levels likely perturb the balance between type I and type II PKA, leading to abnormal cell growth and proliferation (Stergiopoulos and Stratakis, 2003) .
We cloned the one missense and nine nonsense PRKAR1A mutant alleles annotated in HGMD and tested them for interactions against three interactors of the wild-type PRKAR1A (Rual et al., 2005) . All fusion proteins carrying nonsense mutations exhibited dramatically reduced expression in yeast, whereas the missense R74C allele is normally expressed ( Figure S6A ), resembling the expression pattern of mutant PRKAR1A observed in patients (Kirschner et al., 2000) . Despite reduced expression, most mutant proteins preserved one or two wild-type interactions, except for Q28X and Q37X ( Figure S6A ). The two null-like alleles (Q28X and Q37X) truncate the N-terminal RIIα domain of PRKAR1A ( Figure S6B ). The R42X mutant allele, located between the two helices of the helix-turn-helix RIIα domain (Banky et al., 2003) , loses interactions with AKAP10 and PLEKHF2 but preserves the interaction with MGC13057 ( Figure S6A ). The expressed missense allele R74C and three nonsense alleles (K63X, Q304X and S307X) preserve the interaction with AKAP10 ( Figure S6A ), a kinase anchoring protein that binds both type I and type II PKA (Huang et al., 1997b) . This dual specificity of AKAP10 allows differential targeting of type I and type II PKA, crucial for integrated signaling (Huang et al., 1997a) . The interaction of PRKAR1A mutant proteins with AKAP10 could interfere with the binding of functional PKA to AKAP10 and cause additional imbalance between type I and type II PKA. Such an interaction could account for more severe phenotypes reported for patients with expressed mutant PRKAR1A (Horvath et al., 2008) . (Maclean et al., 2002) and I278T (Chen et al., 2006) were obtained from the literature. The activity of CBS P145L was obtained from the CBS mutation database (http://www.uchsc.edu/cbs/cbsdata/cbsmain.htm). Traits  411  357  305  240  177  95  Genes  329  288  249  198  151  83  Diseases  363  315  268  213  164  90  Total mutations  17085  13470  9258  5738  3500  1153  Traits  515  443  355  240  76  12  Genes  482  414  335  230  74  12  Diseases  469  404  330  227  72  12  Total mutations  16539  14967  13120  8531  1525  101  Traits  242  211  191  157  116  65  Genes  203  177  162  135  103  60  Diseases  226  197  177  149  115  65  Total mutations  7587  7167  5871  3770  2371  812  Traits  421  362  290  200  65  10  Genes  398  341  277  194  64  10  Diseases  388  333  271  191  62  10  Total mutations  12356  11101  9616  7107 1318 89
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Minimal fraction of "in-frame mutations in each bin Supplemental table 1 . The number of traits, genes, diseases and total mutations in each bin in Figure 2C and Figure S1 for the analysis of "in-frame" versus "truncating" mutations 
